2024
Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project
Javanbakht A, Stringer S, Anderson H, Hamilton E, Philip A, Waller E, Langston A, Joseph N, Roback J, Schneider T, Sullivan H, Hendrickson J. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project. Journal Of Clinical Apheresis 2024, 39: e22127. PMID: 38803152, DOI: 10.1002/jca.22127.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzylaminesBlood Component RemovalCyclamsFemaleGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHumansMaleMiddle AgedMultiple MyelomaPeripheral Blood Stem Cell TransplantationPlatelet CountRetrospective StudiesTransplantation, AutologousConceptsStem cell collectionPlatelet countG-CSFMultiple myelomaAutologous peripheral blood stem cell collectionApheresis collectionsPeripheral blood stem cell collectionAutologous stem cell collectionBlood stem cell collectionCell collectionPre-emptive plerixaforBaseline platelet countTransplant doseAutologous collectionApheresisPatientsMedical recordsPlerixaforCollection goalDay of collectionQuality improvement initiativesMyelomaPoor mobilityPlateletCountRed blood cell alloimmunization in patients on extracorporeal membrane oxygenation
Javanbakht A, Schneider T, Hendrickson J. Red blood cell alloimmunization in patients on extracorporeal membrane oxygenation. Transfusion 2024, 64: 761-762. PMID: 38593282, DOI: 10.1111/trf.17761.Peer-Reviewed Original Research
2023
Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression
Jajosky R, Patel K, Allen J, Zerra P, Chonat S, Ayona D, Maier C, Morais D, Wu S, Luckey C, Eisenbarth S, Roback J, Fasano R, Josephson C, Manis J, Chai L, Hendrickson J, Hudson K, Arthur C, Stowell S. Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression. Blood 2023, 142: 1082-1098. PMID: 37363865, PMCID: PMC10541552, DOI: 10.1182/blood.2022018591.Peer-Reviewed Original ResearchConceptsAntibody-mediated immunosuppressionRBC alloantigensImmune responseFetal red blood cell antigensTarget antigenRed blood cell antigensRh immune globulinMaternal immune responseBlood cell antigensInclusion of antibodiesRBC removalAnti-RhD antibodiesAbility of antibodiesImmune globulinAntibody responseHemolytic diseaseRBC clearanceCell antigensFetal RBCsAntibody characteristicsAlloantigensSimilar interventionsAntibodiesAntigenPolyclonal antibody preparationIntroduction to a How I Treat series on consultative hematology for inpatients
Hendrickson J, Ortel T. Introduction to a How I Treat series on consultative hematology for inpatients. Blood 2023, 142: 751-752. PMID: 37167420, DOI: 10.1182/blood.2023019877.Peer-Reviewed Original ResearchAssociations of donor, component, and recipient factors on hemoglobin increments following red blood cell transfusion in very low birth weight infants
DeSimone R, Plimier C, Goel R, Hendrickson J, Josephson C, Patel R, Sola‐Visner M, Roubinian N. Associations of donor, component, and recipient factors on hemoglobin increments following red blood cell transfusion in very low birth weight infants. Transfusion 2023, 63: 1424-1429. PMID: 37387597, PMCID: PMC10530070, DOI: 10.1111/trf.17468.Peer-Reviewed Original ResearchConceptsLow birth weight infantsRed blood cell transfusionBirth weight infantsBlood cell transfusionVLBW infantsHemoglobin incrementsTransfusion effectivenessCell transfusionWeight infantsRBC transfusionHemoglobin levelsRecipient factorsBlood donorsSingle-unit RBC transfusionsRBC unitsAssociation of donorDonor hemoglobin levelsTransfusion episodesTransfusion eventsClinical outcomesDonor factorsMultivariable regressionTransfusionDonor sexFemale donorsEnhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease
Nakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Chang A, McLemore M, Rassi F, Roback J, Neish A, Fasano R, Stowell S. Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease. British Journal Of Haematology 2023, 202: 937-941. PMID: 37287128, PMCID: PMC10751105, DOI: 10.1111/bjh.18899.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCOVID-19 vaccinationAntibody responseCell diseaseSARS-CoV-2 vaccinationIgG immune responseSimilar antibody responsesOptimal vaccination strategyIgG titresIgG responsesVaccination strategiesImmune responseSCD controlsGeneral populationPatientsVaccinationDiseaseResponseCohortTitresTransfusion therapy for sickle cell disease: what’s new?
Chou S, Hendrickson J, Fasano R. Transfusion therapy for sickle cell disease: what’s new? Blood Advances 2023, 7: 2551-2553. PMID: 36562748, PMCID: PMC10242629, DOI: 10.1182/bloodadvances.2022009283.Peer-Reviewed Original ResearchEpidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review
Jacobs J, Stephens L, Allen E, Binns T, Booth G, Hendrickson J, Karafin M, Tormey C, Woo J, Adkins B. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. British Journal Of Haematology 2023, 201: 1025-1032. PMID: 37074146, DOI: 10.1111/bjh.18825.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSickle cell diseaseHyperhaemolysis syndromeAnti-globulin testRed blood cellsSupportive transfusionsIndirect anti-globulin testDirect anti-globulin testIntravenous immune globulinHaemolytic transfusion reactionsImmune globulinMedian hemoglobinClinical featuresCommon therapyUnderlying pathophysiologyTransfusion reactionsCell diseaseSevere formTherapeutic strategiesPatientsSystematic reviewBlood cellsTransfusionHyperhaemolysisDaysCorticosteroidsAssociations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis
Bougie D, Reese S, Birch R, Bookwalter D, Mitchell P, Roh D, Kreuziger L, Cable R, Goel R, Gottschall J, Hauser R, Hendrickson J, Hod E, Josephson C, Kahn S, Kleinman S, Mast A, Ness P, Roubinian N, Sloan S, Study‐IV‐Pediatric F. Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis. Transfusion 2023, 63: 960-972. PMID: 36994786, PMCID: PMC10175171, DOI: 10.1111/trf.17319.Peer-Reviewed Original ResearchConceptsPlatelet transfusionsHazard ratioPatient outcomesMulticenter retrospective analysisPlatelet transfusion requirementsGroup O recipientsRecipient's blood groupRisk of mortalitySpecific patient populationsBlood group ARecipient EpidemiologyTransfusion requirementsB recipientsOverall cohortProspective studyO recipientsPatient populationRetrospective analysisPlatelet dosesGroup ATransfusionABO antigensABO groupPatient exposureSignificant associationClass switching is differentially regulated in RBC alloimmunization and vaccination
Prakash A, Medved J, Arneja A, Niebuhr C, Li A, Tarrah S, Boscia A, Burnett E, Singh A, Salazar J, Xu W, Santhanakrishnan M, Hendrickson J, Luckey C. Class switching is differentially regulated in RBC alloimmunization and vaccination. Transfusion 2023, 63: 826-838. PMID: 36907655, PMCID: PMC10851675, DOI: 10.1111/trf.17301.Peer-Reviewed Original ResearchConceptsSTAT6 KO miceSTAT6-deficient miceHOD RBCsRole of STAT6IgG subtypesRBC alloimmunizationKO miceDeficient miceTotal IgG responseIgG subclass distributionRBC transfusionIgG responsesWT miceAntibody responseIgG3 subclassSubclass distributionIgG subclassesMouse modelHuman patientsVaccinationMiceStudy designAltered levelsSubtypesClass switching
2022
Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis
Kerantzas CA, Merwede J, Snyder EL, Hendrickson JE, Tormey CA, Kazmierczak BI, Peaper DR. Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis. Transfusion 2022, 62: 2458-2463. PMID: 36178430, PMCID: PMC11472026, DOI: 10.1111/trf.17136.Peer-Reviewed Original ResearchConceptsAcinetobacter calcoaceticus-baumannii complexBlood productsS. saprophyticusPlatelet unitsContaminated blood productsCDC investigationsApheresis platelet productsTransfusion reactionsPolymicrobial contaminationPlatelet productsDisease controlBacterial isolatesStudy designStaphylococcus saprophyticusPolymicrobial interactionsCDC casesSaprophyticusFuture studiesPotential interactionsCommon sourceSepsisIsolatesCasesCoaggregationClodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice
Arthur CM, Patel SR, Sharma A, Zerra PE, Chonat S, Jajosky RP, Fasano RM, Patel R, Bennett A, Zhou X, Luckey CJ, Hudson KE, Eisenbarth SC, Josephson CD, Roback JD, Hendrickson JE, Stowell SR. Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion 2022, 62: 948-953. PMID: 35470900, PMCID: PMC9491148, DOI: 10.1111/trf.16872.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationRBC transfusionAntibody formationPreclinical modelsRed blood cell transfusionBlood cell alloantigensBlood cell transfusionTransfusion of RBCsTransfusion-dependent patientsDevelopment of alloantibodiesIgG antibody formationAlloantigen exposureHOD RBCsCell transfusionPost transfusionAlloantibody formationPharmacological removalIgG antibodiesTransfusionAlloimmunizationClodronateMarginal sinusPrior treatmentDay 5KEL antigenThe Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan
Josephson CD, Glynn S, Mathew S, Birch R, Bakkour S, Kreuziger L, Busch MP, Chapman K, Dinardo C, Hendrickson J, Hod EA, Kelly S, Luban N, Mast A, Norris P, Custer B, Sabino E, Sachais B, Spencer BR, Stone M, Kleinman S, for the National Heart L. The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan. Transfusion 2022, 62: 982-999. PMID: 35441384, PMCID: PMC9353062, DOI: 10.1111/trf.16869.Peer-Reviewed Original ResearchConceptsBlood safety issueRecipient outcomesData Coordinating CenterRecipient EpidemiologySevere acute respiratory syndrome corona virus 2Blood donor safetyNon-transfused patientsProspective observational studyHospital electronic medical recordsCorona virus 2Sickle cell diseaseElectronic medical recordsPreterm infantsDonor safetyNational HeartMedical recordsBlood donorsCell diseaseObservational studyBlood supplyTransfusion outcomesBlood centersStudy designSpecial populationsCoordinating CenterInternational guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn
Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz‐Diaz E, Nahirniak S, New HV, Pavenski K, dos Santos M, Ramsey G, Shehata N, Guidelines F. International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn. British Journal Of Haematology 2022, 198: 183-195. PMID: 35415922, PMCID: PMC9324942, DOI: 10.1111/bjh.18170.Peer-Reviewed Original ResearchConceptsRole of IVIGIntravenous immunoglobulinExchange transfusionHaemolytic diseaseSafety of IVIGRed blood cell transfusionBlood cell transfusionDuration of hospitalizationSeverity of anemiaEvidence-based recommendationsHigh-quality studiesCell transfusionPrompt treatmentBilirubin levelsSignificant morbidityAlternative therapiesIntensive phototherapyNeurocognitive outcomesManagement of RhInternational guidelinesTransfusionNewbornsDiseasePhototherapyInternational panelInnate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88.
Soldatenko A, Hoyt LR, Xu L, Calabro S, Lewis SM, Gallman AE, Hudson KE, Stowell SR, Luckey CJ, Zimring JC, Liu D, Santhanakrishnan M, Hendrickson JE, Eisenbarth SC. Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88. The Journal Of Immunology 2022, 208: 991-997. PMID: 35039331, PMCID: PMC10107373, DOI: 10.4049/jimmunol.2100784.Peer-Reviewed Original ResearchConceptsPattern recognition receptorsDendritic cellsDC activationAdaptive immunityClass of PRRsNon-ABO alloantibodiesRecipient dendritic cellsSplenic dendritic cellsMouse RBCsInflammatory cytokine responseTreatment of anemiaRBC transfusion therapyTransfused RBCsAlloantibody responsesAllogeneic RBCsSerious complicationsCytokine responsesTransfusion therapyRecognition receptorsMyD88TransfusionAlloimmunizationRBCsTRIFUnknown mechanismEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian ageDonor genetic and non-genetic factors affecting red blood cell transfusion effectiveness
Roubinian NH, Reese SE, Qiao H, Plimier C, Fang F, Page GP, Cable RG, Custer B, Gladwin MT, Goel R, Harris B, Hendrickson JE, Kanias T, Kleinman S, Mast AE, Sloan SR, Spencer BR, Spitalnik SL, Busch MP, Hod EA, . Donor genetic and non-genetic factors affecting red blood cell transfusion effectiveness. JCI Insight 2022, 7: e152598. PMID: 34793330, PMCID: PMC8765041, DOI: 10.1172/jci.insight.152598.Peer-Reviewed Original ResearchConceptsTransfusion effectivenessHemoglobin incrementsRBC transfusionG6PD deficiencyMulticenter retrospective studyRBC storage durationRBC unit transfusionPrecision medicine approachSubset of donorsTransfusion episodesTransfusion requirementsUnit transfusionRecipient factorsRetrospective studyRBC recipientsPatient outcomesRecipient characteristicsChild healthTransfusionVivo hemolysisTransfusion productsMedicine approachNon-genetic factorsOxidative hemolysisSingle nucleotide polymorphisms
2021
Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor
Jacobs JW, Guarente J, Hendrickson JE, Tormey CA, Bar N. Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor. Journal Of Clinical Apheresis 2021, 37: 316-319. PMID: 34953078, DOI: 10.1002/jca.21962.Peer-Reviewed Original ResearchConceptsCellular therapy productsHematopoietic stem cellsAllogeneic blood productsAutologous hematopoietic stem cellsHematopoietic stem cell productsPathogenic Gram-negative organismsNormal skin floraTherapy productsCase of SalmonellaStem cell productsGram-negative organismsAsymptomatic donorsTherapeutic dilemmaBlood productsPathogen reduction technologySkin floraHSC productsAdverse effectsCell productsPrior reportsSignificant reductionStem cellsSalmonellosisSalmonella bacteriaMost microorganismsManagement of hemolytic transfusion reactions
Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology 2021, 2021: 704-709. PMID: 34889404, PMCID: PMC8791106, DOI: 10.1182/hematology.2021000308.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesSevere DHTRTransfusion reactionsRed blood cell transfusionDisease-specific risk factorsPathway activationMultiple RBC alloantibodiesBlood cell transfusionSymptoms of painStem cell transplantationSafety of transfusionSickle cell diseaseClassic pathway activationAlternative pathway activationTransfusion avoidanceCell transfusionCurative therapyCell transplantationPatient's hemoglobinRisk factorsTransfusion safetyCell diseaseDHTRHgb ARBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?
Lee ES, Hendrickson JE, Tormey CA. RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary? Transfusion 2021, 61: 3283-3285. PMID: 34767268, DOI: 10.1111/trf.16736.Peer-Reviewed Original ResearchConceptsRBC alloimmunization